samedan logo
 
 
spacer
home > pmps > summer 2002 > providing global access to medicines - the role of manufacture and supply
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Providing Global Access to Medicines - The Role of Manufacture and Supply

A universally held objective is patient 'access' to health care interventions in general and medicines in particular - both patent-protected and generic. This represents a particular problem for patients in developing countries, many of whom (for a variety of reasons) do not currently have access. The barriers are multi-factorial: physical and health care infrastructures are often inadequate; financial resources are limited; military, social and political issues abound and country economic policies can have negative effects on health care provision. It is clear that these problems cannot be solved by initiatives in manufacture and supply (M&S), but at the same time some attention has been focused on whether local production, generic competition and technology transfer might make a significant contribution.

Unfortunately, much of the policy discussion within this area has been undertaken without an understanding or appreciation of modern pharmaceutical M&S. This article describes some of the key considerations, and highlights the access-related policy implications. There are five principal considerations, which largely apply equally to branded products and generics:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Webber, Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Dr David Webber is a Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) in Geneva. David gained a degree in Biology and a PhD in Animal Physiology from London University, and then undertook postdoctoral research, which led to published papers on stomach function.
He joined Glaxo Pharmaceuticals in 1982, and was responsible for various marketing functions in the UK Operating Company, before assuming a role in the corporate strategy unit. In 1999, David was appointed Public Policy Director in the Corporate Policy and Public Affairs group. In 2000, David was seconded to IFPMA, where he is responsible for policy development in key areas for the industry.

spacer
David Webber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement